Some good news: announcing Longevity2020

In these challenging times, with everyone working from home and conferences pushed-back to later this year, we had an idea: Longevity2020

While the world overcomes COVID19, work in Longevity, for many, goes on. So we thought: let’s stage a worldwide Longevity conference!

Longevity.Technology: You’re at home, so are we… so are most of the experts in Longevity. So, let’s get together. Learn, share knowledge, build our networks and take a break from Netflix.

Longevity2020 is 100% digital – we will bring together the experts, the innovators, the investors, and the curious (online) for 2.5hrs each day over 5 fascinating days.

We’ll be using the latest online event technology to provide you with an amazing experience: you’ll receive full video and media rich presentations. At the end of each session, our platform provides you with access to other delegates through unique networking software.

Pre-registration is now open now. Once we’re happy that we have our launch programme of speakers and subjects sufficiently ready we’ll switch ticketing to live. Sessions will be over 2.5 hours each day and will start: 5pm EU: 4pm UK: 11am EST: 8am PST


Here’s the outline agenda:

Monday 27 April: Rejuvenation therapies:

What’s the latest in: senolytics, gene editing, immunotherapy,  mitochondrial restoration, indication expansion, neutraceuticals, peptides, stem cells…

Tuesday 28 April: Longevity: start now

What can you be doing to address your Longevity now: supplements, metformin, mTOR, NAD+, rapamycin, biohacking, fasting, biomarker tracking, monitoring apps…

Wednesday 29 April: AI and Longevity

How is AI accelerating Longevity and where: molecule identification, pre-clinical validation, digital health, lifestyle interventions, finance…

Thursday 30 April: Longevity investing

It’s all about growing the investment category: risk management, going public, investment platforms, emerging tech:  3D bio-printing, neuroceuticals, organ growth, agetech…

Friday 01 May: Biomarkers of aging

Addressing the need for a baseline: cellular senescence, methylation, telomere length, metabolomics, inflammation, congnition, function, ageotype…


 

We’re just lining-up our curators and speakers. Please pre-register for updates… or apply to present! 

We hope you, your family and your colleagues are all keeping well. Our team is located in London, Paris and Berlin – we’re staying positive and trust you are too. Best wishes 🙂

Phil Newman
Editor-in-Chief Phil is Editor-in-Chief Longevity.Technology and founder of Crowd Longevity a digital investment platform for international investors and Longevity start-ups launching in 2020.

In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.

Latest articles

Peptide molecule causes cancer cells to self destruct

New breakthrough by a team led by eminent oncologist Loren Walensky brings new hope for future cancer treatments – and Longevity.  Everyone needs a way...

WHO portal brings aging data together

We live in a world driven by data and the World Health Organization (WHO) has now launched the first data portal to bring together...

The natural medicine war chest to fight aging

Quicksilver's liposomal delivery system boasts a non-invasion of the body patchers. Colorado-based Quicksilver Scientific manufactures a range of supplements from immunity boosters to NAD+. By...

Jim Mellon and Phil Newman: Longevity interviews

Master Investor is a publication that helps private investors to take charge of their financial destiny: covering a range of subjects, from shares to...